Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Paul Stoffels
Biotech
'Gilead wants us to rebuild': Why Galapagos can't go extinct
CEO Paul Stoffels has left, and his cell therapy strategy has been scrapped. So what happened to Galapagos?
James Waldron
Nov 19, 2025 7:50am
Galapagos sends respiratory drug back to Molecure
Jun 24, 2022 9:37am
Paul Stoffels lays out 5-year plan to turn Galapagos around
Jun 23, 2022 8:49am
Galapagos takes M&A plunge, spending $251M for CAR-T push
Jun 22, 2022 4:36am
New Galapagos CEO Stoffels jumps into deals, key hiring decision
Jan 27, 2022 12:00pm
J&J science chief Stoffels to retire, adding to C-suite changes
Oct 12, 2021 8:50am
